Sanofi’s New Phase 2a Study: A Potential Game-Changer in Kidney Disease Treatment

Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.

Sanofi SA has initiated a Phase 2a clinical study titled A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD). The study aims to assess the efficacy and safety of these drugs in reducing proteinuria and achieving remission in nephrotic syndrome among patients with primary FSGS or MCD.

The interventions being tested include Frexalimab, SAR442970, and Rilzabrutinib, all of which are experimental drugs designed to treat FSGS and MCD by potentially reducing proteinuria levels.

This interventional study employs a randomized, parallel-group design with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide new therapeutic options for these kidney conditions.

The study began on December 19, 2024, with an estimated completion timeline of 76 weeks, including a 24-week treatment period. The latest update was submitted on August 12, 2025, indicating ongoing recruitment and progress.

For investors, this study represents a significant opportunity for Sanofi to strengthen its position in the nephrology market. Positive outcomes could enhance Sanofi’s stock performance and investor confidence, especially given the competitive landscape in developing treatments for kidney diseases.

The study is currently ongoing, with further details available on the ClinicalTrials portal.